Wegovy-maker Novo Nordisk to slash 9,000 jobs as competition heats up

Novo Nordisk is undertaking a major restructuring, including cutting 9,000 jobs (11.5% of its workforce), to achieve $1.3 billion (8 billion DKK) in annual savings. This strategic shift, which will incur 9 billion DKK in Q3 restructuring costs, is a direct response to intensifying competition from Eli Lilly and slowing market share and sales growth for its blockbuster drugs Wegovy and Ozempic, particularly in the U.S. CEO Mike Doustdar emphasized the need to evolve amid a more competitive obesity market, leading to a revised operating profit growth forecast for the year from 10-16% down to 4-10% due to these costs, while analysts anticipate a positive market reaction to the cost-saving measures.

Analysis

Novo Nordisk is undertaking a significant restructuring to counter slowing growth and mounting competitive pressure from Eli Lilly. The plan involves a workforce reduction of 9,000 employees, or 11.5% of its total staff, with the goal of achieving approximately $1.3 billion (8 billion DKK) in annual savings. This strategic overhaul comes as the company's key products, Wegovy and Ozempic, experience market share erosion, particularly in the United States, exacerbated by the availability of copycat medicines from compounders. The financial impact includes a one-off restructuring charge of 9 billion DKK in the third quarter, which has prompted a downward revision of the full-year operating profit growth forecast to 4-10%, from a previous range of 10-16%. Notably, the company states this guidance change is solely due to the restructuring costs. This decisive action by new CEO Mike Doustdar follows a period of extreme market pressure, with the company's shares having fallen nearly 46% year-to-date and its market capitalization contracting from a peak of around $650 billion to $181 billion. Despite the job cuts, the move is being interpreted by analysts as a necessary, albeit "tough," measure to "clear the decks" and reposition the company for future growth in a more competitive landscape.

Key Decisions for Investors

• Consider that the aggressive $1.3 billion cost-cutting plan, while painful, is a decisive action by new management that could establish a more competitive cost base and signal a potential turning point for the stock.
• Investors should closely monitor upcoming quarterly sales figures for Wegovy and Ozempic to gauge if this restructuring is sufficient to stabilize market share against intense competition from Eli Lilly and compounders.
• It is crucial to look past the one-off 9 billion DKK Q3 restructuring charge and focus on underlying operational performance and management's forward guidance in the next earnings call for a true measure of the business's health.